Drug interactions
Encorafenib + Linagliptin
Severity: Minor
Encorafenib and Linagliptin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib both inhibits and induces CYP3A4, so linagliptin exposure may be altered unpredictably. Linagliptin's mostly non-metabolic elimination limits the likely impact.
What this interaction means in plain words
Encorafenib and Linagliptin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Encorafenib belongs to Oncology; Linagliptin belongs to Endocrine.
Why it happens
Mixed CYP3A4 inhibition and induction by encorafenib alters linagliptin metabolism.
What to do
No empirical dose change; monitor glucose control during co-therapy.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Linagliptin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Linagliptin
- Alogliptin-pioglitazone + Linagliptin Moderate
- Amlodipine-benazepril + Linagliptin Moderate
- Amobarbital + Linagliptin Moderate
- Apalutamide + Linagliptin Moderate
- Benazepril + Linagliptin Moderate
- Bexarotene + Linagliptin Moderate
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Linagliptin?
MediHelp rates the interaction as minor. Encorafenib and Linagliptin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Encorafenib both inhibits and induces CYP3A4, so linagliptin exposure may be altered unpredictably. Linagliptin's mostly non-metabolic elimination limits the likely impact.
How serious is the interaction between Encorafenib and Linagliptin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No empirical dose change; monitor glucose control during co-therapy.
What other medicines interact with Linagliptin?
MediHelp also lists interactions of Linagliptin with, for example, Alogliptin-pioglitazone, Amlodipine-benazepril, Amobarbital. The full list is on the Linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
